Brook Baker, a Northeastern University law professor who specializes in access to medicines, said it was unconscionable that rich countries would dip into COVAX vaccine supplies when more than 90 developing countries had virtually no access. COVAX’s biggest supplier, the Serum Institute of India, stopped sharing vaccines in April to deal with a surge of cases on the subcontinent.
Although the number of vaccines being bought by rich countries like Britain through COVAX is relatively small, the extremely limited global supply means those purchases result in fewer shots for poor countries. So far, the initiative has delivered less than 10% of the doses it promised.
COVAX is run by the World Health Organization, the vaccine alliance Gavi and the Coalition for Epidemic Preparedness Innovations, a group launched in 2017 to develop vaccines to stop outbreaks. The program is now trying to regain credibility by getting rich countries to distribute their donated vaccines through its own system, Baker said. But even this effort is not entirely successful because some countries are making their own deals to curry favorable publicity and political clout.
“Rich countries are trying to garner geopolitical benefits from bilateral dose-sharing,” Baker noted.
So far, with the exception of China, donations are coming in tiny fractions of what was pledged, an Associated Press tally of vaccines promised and delivered has found.
Dr. Christian Happi, an infectious diseases expert at Nigeria’s Redeemer’s University, said donations from rich countries are both insufficient and unreliable, especially as they have not only taken most of the world’s supplies but are moving on to vaccinate children and considering administering booster shots.
Happi called on Africa, where 1.5 percent of the population is fully vaccinated, to increase its own vaccine manufacturing rather than rely on COVAX.
“We cannot just wait for them to come up with a solution,” he said.
COVAX is well aware of the problem. During its last board meeting in late June, health officials conceded they had failed to achieve equitable distribution. But they still decided against blocking donor countries from buying up supplies themselves.
At a subsequent meeting with partners, Gavi CEO Dr. Seth Berkley said COVAX intended to honor the agreements it had made with rich countries but would ask them in the future to “adjust” their allocated doses to request fewer vaccines, according to a meeting participant who spoke about the confidential call on condition of anonymity.
Among the reasons Berkley cited for Gavi’s reluctance to break or renegotiate contracts signed with rich countries was the potential risk to its balance sheet. In the last year, Britain alone has given more than $860 million to COVAX.
Meeting notes from June show that Gavi revised COVAX’s initial plan to split vaccines evenly between rich and poor countries and proposed that poor countries would receive about 75% of COVID-19 doses in the future. Without rich countries’ involvement in COVAX, Gavi said “it would be difficult to secure deals with some manufacturers.”
In response to an AP request for comment, Gavi said the initiative is aiming to deliver more than 2 billion doses by the beginning of 2022 and described COVAX as “an unprecedented global effort.”
“The vast majority of the COVAX supply will go to low- and middle-income countries,” Gavi said in an email about its latest supply forecast. For many countries, it said, “COVAX is the main, if not the only source of COVID-19 vaccine supply.”